Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
6.66
+0.16 (2.46%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Biodexa Pharmaceuticals Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.08 | 0.38 | 0.7 | 0.58 | 0.34 | 0.67 | Upgrade
|
| Revenue Growth (YoY) | -84.31% | -45.49% | 20.93% | 68.51% | -49.11% | -65.22% | Upgrade
|
| Cost of Revenue | -0.06 | - | 5.11 | 4.65 | 6.07 | 7.84 | Upgrade
|
| Gross Profit | 0.15 | 0.38 | -4.41 | -4.08 | -5.73 | -7.17 | Upgrade
|
| Selling, General & Admin | 2.78 | 3.03 | 3.18 | 2.95 | 4.96 | 4.16 | Upgrade
|
| Research & Development | 3.97 | 3.97 | - | - | - | - | Upgrade
|
| Other Operating Expenses | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | Upgrade
|
| Operating Expenses | 6.73 | 6.99 | 3.16 | 2.92 | 4.95 | 4.15 | Upgrade
|
| Operating Income | -6.58 | -6.6 | -7.57 | -7 | -10.67 | -11.32 | Upgrade
|
| Interest Expense | -0.07 | -0.04 | -0.05 | -0.04 | -0.03 | -0.1 | Upgrade
|
| Interest & Investment Income | 0.15 | 0.08 | 0.03 | - | 0 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.85 | 0.49 | 0.47 | 0.94 | -0.4 | 0.48 | Upgrade
|
| EBT Excluding Unusual Items | -5.65 | -6.08 | -7.13 | -6.11 | -11.1 | -10.92 | Upgrade
|
| Merger & Restructuring Charges | -0.1 | -0.1 | - | - | - | - | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -2.29 | - | Upgrade
|
| Asset Writedown | - | - | - | - | -10.08 | - | Upgrade
|
| Other Unusual Items | -1.31 | -1.31 | -1.36 | - | - | - | Upgrade
|
| Pretax Income | -7.06 | -7.49 | -8.49 | -6.11 | -23.47 | -10.92 | Upgrade
|
| Income Tax Expense | -0.24 | -0.41 | -0.83 | -0.65 | -1.28 | -1.79 | Upgrade
|
| Earnings From Continuing Operations | -6.82 | -7.08 | -7.66 | -5.46 | -22.19 | -9.14 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | -0.95 | Upgrade
|
| Net Income | -6.82 | -7.08 | -7.66 | -5.46 | -22.19 | -10.09 | Upgrade
|
| Net Income to Common | -6.82 | -7.08 | -7.66 | -5.46 | -22.19 | -10.09 | Upgrade
|
| Shares Outstanding (Basic) | 0 | 0 | - | - | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 0 | 0 | - | - | - | - | Upgrade
|
| EPS (Basic) | -35.76 | -224.13 | - | - | - | - | Upgrade
|
| EPS (Diluted) | -35.76 | -224.13 | - | - | - | - | Upgrade
|
| Free Cash Flow | -7.77 | -6.85 | -7.11 | -6.33 | -9.51 | -6.8 | Upgrade
|
| Free Cash Flow Per Share | -40.77 | -216.94 | - | - | - | - | Upgrade
|
| Gross Margin | 174.70% | 100.00% | - | - | - | - | Upgrade
|
| Operating Margin | -7931.33% | -1733.33% | -1083.26% | -1210.73% | -3111.08% | -1679.23% | Upgrade
|
| Profit Margin | -8215.66% | -1858.01% | -1095.28% | -944.64% | -6469.10% | -1496.29% | Upgrade
|
| Free Cash Flow Margin | -9366.27% | -1798.43% | -1017.17% | -1094.81% | -2772.59% | -1008.75% | Upgrade
|
| EBITDA | -6.44 | -6.46 | -7.4 | -6.79 | -9.57 | -10.34 | Upgrade
|
| D&A For EBITDA | 0.14 | 0.15 | 0.18 | 0.21 | 1.1 | 0.98 | Upgrade
|
| EBIT | -6.58 | -6.6 | -7.57 | -7 | -10.67 | -11.32 | Upgrade
|
| Revenue as Reported | - | - | - | - | 0.34 | 0.67 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.